ASH 2021: Updates in CLL

ASH 2021: Updates in CLL

Ibrutinib Plus Fludarabine, Cyclophosphamide, and Rituximab for Younger Patients With CLL

Study results demonstrate that a 2.5-year regimen involving ibrutinib and chemoimmunotherapy may provide deep and lasting remissions for young, fit patients with CLL.

The ASCO Post
Ibrutinib Plus Rituximab Is Superior to FCR in Previously Untreated CLL

Ibrutinib plus rituximab appears to have superior efficacy relative to the combination of fludarabine, cyclophosphamide, and rituximab in previously untreated chronic lymphocytic leukemia.

Hematology Advisor
Umbralisib Plus Ublituximab Benefits Patients With CLL and Bruton TKI Risk Factors

The combination of umbralisib and ublituximab demonstrated superior PFS and overall response rates compared with chemoimmunotherapy among patients with CLL...


Zanubrutinib Improves PFS, But May Not Improve OS, in Patients With Treatment-Naïve CLL/SLL

Among patients with treatment-naïve CLL/SLL, zanubrutinib appears to improve PFS, but not the complete response rate or overall survival rate, compared with bendamustine plus rituximab.

Hematology Advisor
Real-World Study Illuminates Shifting CLL Treatment Trends

An analysis of real-world data regarding the treatment of patients with chronic lymphocytic leukemia revealed that standards of care are shifting from chemoimmunotherapy to targeted therapies. These findings were presented as a poster at the 2021 ASH Annual Meeting.

ASH 2021 Plans a Hybrid Format—With COVID-19, CAR T, and Health Equity on the Agenda

In recent weeks, the scientific meeting circuit has crept back to life from the COVID-19 pandemic. But the biggest test to date will come this weekend in Atlanta, when the 63rd American Society of Hematology Meeting and Exposition gathers December 11-14 at the Georgia World Congress Center, with a virtual format option for those who prefer to participate remotely.

Combinations Produced Durable Responses in High-Risk Chronic Lymphocytic Leukemia

Fixed-duration treatment with obinutuzumab plus venetoclax or ibrutinib can produce durable responses in patients with CLL at high risk of relapse, according to a pooled analysis of phase 2 trials.

Cancer Therapy Advisor
InnoCare to Present Orelabrutinib Data at the Upcoming 63rd Annual Meeting of ASH

BEIJING, Nov. 9, 2021 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a leading biotech company, announced today that the company will present latest data of its BTK inhibitor orelabrutinib at the 63rd American Society of Hematology (ASH) Annual Meeting on December 11-14, 2021, which will be hold online and offline in Atlanta, Georgia.

AstraZeneca Advances Ambition to Redefine Care for Blood Cancer at ASH 2021

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca will present new data underscoring its commitment to transforming hematologic cancer care at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition, December 11 to 14, 2021.

BeiGene to Present Clinical Data on BRUKINSA in Chronic Lymphocytic Leukemia at the 63rd ASH Annual Meeting

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)--BeiGene, a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, announced clinical results and real world data from its hematology program to be presented at the 63rd ASH Annual Meeting and Exposition, including two oral presentations on the Phase 3 SEQUOIA trial comparing BRUKINSA® (zanubrutinib) to bendamustine and rituximab (B+R) in patients with treatment-naïve CLL or SLL. The ASH meeting will take place on December 11-14, 2021, as a hybrid event in Atlanta, GA and in a virtual format.

Autolus Therapeutics to Present New Data at the 63rd ASH Annual Meeting & Exposition

LONDON, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc, a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announced an oral presentation related to the industrialization of its manufacturing process and poster presentations related to its obe-cel (AUTO1) and AUTO1/22 programs, the company’s CAR T cell product candidates being investigated in adult ALL (the FELIX study) and Pediatric ALL (the CARPALL study), respectively, at the 63rd ASH Annual Meeting & Exposition, being held between December 11-14, 2021. 


source list reference

rgb(171, 222, 222)
rgb(219, 18, 118)
200, 66, 245
rgb(195, 2, 230)
rgb (247, 7, 79)
rgb(14, 133, 237)
rgb(252, 3, 223)
rgb(209, 15, 15)
rgb(115, 43, 196)
rgb(9, 151, 227)
rgb(252, 186, 3)
rgb(242, 0, 137)
rgb (247, 7, 79)
rgb(48, 38, 189)
rgb(231, 165, 240)
rgb(230, 21, 49)
rgb (252, 186, 3)
rgb(156, 242, 7)
rgb(91, 128, 189)
rgb(247, 139, 109)
rgb(224, 4, 129)
rgb(20, 13, 222)
rgb(84, 54, 94)
rgb(80, 147, 199)
rgb(117, 2, 247)
rgb(153, 146, 129)
rgb(11, 160, 224)
rgb(245, 111, 66)
rgb (245, 152, 2)
rgb(164, 116, 173)
rgb(219, 105, 96)
rgb(66, 135, 245)
rgb(169, 196, 201)
rgb(125, 127, 130)
rgb(5, 235, 235)
rgb(235, 190, 9)
rgb(209, 227, 11)
200, 66, 245
rgb (191, 171, 145)
rgb(126, 14, 237)
rbg(167, 124, 235)
rgb (132, 101, 173)
rgb((217, 11, 193)
rbg(16, 162, 230)
rgb(217, 7, 192)
rgb(107, 129, 201)
rgb (214, 104, 96)
rgb(224, 224, 4)
rgb(2, 230, 230)
rgb(186, 130, 237)
rgb(235, 64, 52)
rgb(214, 139, 202)